Welcome  |   Program  |   Registration  |   Hotel  |   Support and Exhibitors
Meeting Program
Continuing Medical Education (CME) is jointly provided by
the American Association for Cancer Research (AACR) and the
Association of American Cancer Institutes (AACI)
Sunday, October 15
8:00-10:30 am

AACI Board of Directors Meeting (closed meeting)

11:00-12:30 pm

Corporate Roundtable Meeting (closed meeting)

11:00 am

Meeting Registration Begins

11:00 am

Exhibits Open

General Session

1:00 pm

Welcome and AACI Business Meeting

President’s Report
Dr. Stanton L. Gerson
Case Comprehensive Cancer Center

Executive Director’s Report
Ms. Barbara Duffy Stewart
Association of American Cancer Institutes

Treasurer’s Report
Mr. Randy Main
Fred Hutchinson Cancer Research Center

Program Chair’s Report
Dr. Karen Knudsen
Sidney Kimmel Cancer Center at Thomas Jefferson University

CCAF Report
Mr. David M. Gosky
UK Markey Cancer Center

1:45 pm

Opening Keynote Speaker
Mr. Collender will focus his talk on the proposed budget cuts to biomedical research and the impact the cuts will have on academic cancer centers and their ability to care for patients. This topic will be addressed from Mr. Collender's unique perspective as both a federal budget expert and a cancer survivor.

Mr. Stan Collender
Qorvis MSLGROUP

2:45 pm

Break

3:00 pm

Impact of the New CCSG Guidelines on the Cancer Centers
This panel discussion will explore the practical ramifications of recently revised guidelines for NCI’s Cancer Center Support Grant, especially as they relate to optimal means of compliance. Selected cancer centers that are preparing, or have recently completed, core grant submissions will be highlighted.

Moderator: Dr. Cheryl L. Willman
University of New Mexico Comprehensive Cancer Center

Dr. Howard Bailey
University of Wisconsin Carbone Cancer Center

Dr. Eric Fearon
University of Michigan Comprehensive Cancer Center

Dr. Randall F. Holcombe
University of Hawai'i Cancer Center
University of Hawai'i at Manoa

4:00 pm

General Sessions End

4:00-4:30 pm

CCAF Business Meeting
(closed session for members of CCAF)

4:00-6:00 pm

5th Annual AACI Physician Clinical Leadership Initiative Meeting
Agenda - Please RSVP to attend this special session

6:00-7:30 pm

Welcome Reception

7:30 pm

Dinner on your own

Monday, October 16
7:00 am

General Breakfast

7:00 am

Exhibits Open

8:00 am

Update on the Network Care Initiative
Many cancer center hospital systems are expanding their services across large geographic regions, while cancer care is consolidating around ever enlarging groups. AACI’s Network Care Initiative aims to better define these networks and to develop methods of improving the quality of cancer care administered across individual cancer center networks, with better integration of treatment services, especially those now unique to our centers, into the community. AACI President Dr. Stanton Gerson will provide an update on the initiative, including results of a survey about the current status of networks.

Dr. Stanton L. Gerson
Case Comprehensive Cancer Center

8:30 am

Outreach in Community Networks – Challenges and Opportunities
Without a clear roadmap, managing cancer center networks is a challenging, complex task. Ensuring that the same level of consistent, high quality care delivered at the flagship facility is experienced by patients at satellite locations requires uniform policies and procedures. Panelists will address some of the issues that AACI cancer centers face in operating their networks, such as employment network models, referral patterns, access to clinical trials, use of care paths, and monitoring quality care.

Moderator: Dr. Stanton L. Gerson
Case Comprehensive Cancer Center

Dr. Gerold Bepler
Barbara Ann Karmanos Cancer Institute
Wayne State University

Dr. Brian J. Bolwell
Cleveland Clinic Taussig Cancer Institute
The Cleveland Clinic Foundation

Dr. Karen Knudsen
Sidney Kimmel Cancer Center at Thomas Jefferson University


9:30 am

Distinguished Scientist Award Presentation
Dr. June's talk will revolve around his ongoing work and recent FDA approval of gene transfer therapy to treat cancer. Clinical trials utilizing this approach, in which patients are treated with genetically engineered versions of their own T cells, are now underway for adults with chronic lymphocytic leukemia and adults and children with acute lymphoblastic leukemia. Trials of this approach have also begun for patients with other blood cancers and solid tumors including pancreatic cancer, mesothelioma, and the brain cancer glioblastoma. The implications of the first approval of gene transfer therapy by the US FDA will be discussed.

Tcell therapy for Cancer
Dr. Carl June
Abramson Cancer Center of the University of Pennsylvania

10:30 am

Break

10:45 am

New CCSG section: Training and Education
(concurrent session)
A new component of NCI's Cancer Center Support Grant application, "Cancer Research Career Enhancement and Related Activities", highlights efforts to coordinate and enhance existing cancer research education, training, and career development activities. Panelists will address the general structure of the new section, its scope and expectations, and appropriate items to highlight and outcomes to document. They will also provide specific examples of how centers completed the new section in recent CCSG applications.

Moderator: Mr. David M. Gosky
UK Markey Cancer Center

Ms. Jane Welter
Mayo Clinic Cancer Center

Mr. Alex Zafirovski
The Robert H. Lurie Comprehensive Cancer Center
Northwestern University

10:45 am

Immunotherapy: The End of the Beginning?
(concurrent session)
Growing momentum in the successful implementation of immunotherapeutic strategies has shifted the patient care model, raising immunotherapy’s profile as the fourth pillar in the standard of care, joining surgery, chemotherapy and radiotherapy. This panel discussion will highlight various recent technological breakthroughs in areas including the underlying mechanisms of chronic lymphocytic leukemia and immune checkpoint inhibition in the tumor microenvironment.
                                                   
Moderator: Dr. Laurie H. Glimcher
Dana-Farber Cancer Institute
Harvard Medical School

Dr. Juan Cubillos-Ruiz
Weill Cornell Medical College, Cornell University

Dr. Padmanee Sharma
University of Texas MD Anderson Cancer Center

Dr. Catherine J. Wu
Dana-Farber Cancer Institute
Harvard Medical School

11:45 am

Break

12:00 pm

Luncheon

1:00 pm

Networking and Dessert in the Foyer

2:00 pm

Clinical Trial Deployment Within the Community
Conducting effective cancer clinical trials often requires engagement by both community and academic partners in a myriad of activities spanning protocol design through dissemination of study findings. Such cooperation can increase accrual of underserved and underrepresented populations. Panelists will explore methods of improving clinical trial management, strategic planning and project implementation to boost research participation by underrepresented diverse populations and to improve cancer prevention and control programming.

Moderator: Dr. Victor M. Santana
Comprehensive Cancer Center St. Jude Children’s Research Hospital

Dr. Robert L. Ferris
UPMC Hillman Cancer Center

Dr. Roy Jensen
The University of Kansas Cancer Center

Ms. Teresa L. Stewart
University of New Mexico Comprehensive Cancer Center

3:15 pm

Break

3:30 pm

Practical Advice for a Successful CCSG Submission
(concurrent session)
Optimal means of compliance with NCI Cancer Center Support Grant (CCSG) guidelines will be explored in this session, with particular focus on selected cancer centers that have recently completed core grant submissions. The practical ramifications of preparing a CCSG competing renewal will be reviewed, and practical advice will be offered regarding different approaches for free-standing versus matrix cancer centers.

Moderator: Mr. Alex Zafirovski
The Robert H. Lurie Comprehensive Cancer Center
Northwestern University

Ms. Julie Brabbs
University of Michigan Comprehensive Cancer Center

Mr. Peter Connor
University of Wisconsin Carbone Cancer Center

Mr. David M. Gosky
UK Markey Cancer Center

Mr. Matthew Huesser
Sidney Kimmel Cancer Center at Thomas Jefferson University

Dr. Alan McClelland
University of Texas MD Anderson Cancer Center

3:30 pm

Precision Medicine Update
(concurrent session)
The impact of recent scientific discoveries related to precision medicine will be the focus of this session, with panelists highlighting their recent work, including resistance to targeted therapy and advances in the areas of prostate and lung cancer and leukemia.

Moderator: Dr. Gerold Bepler
Barbara Ann Karmanos Cancer Institute
Wayne State University

Dr. Eric B. Haura
Moffitt Cancer Center

Dr. Jill M. Kolesar
UK Markey Cancer Center

Dr. Nikhil Wagle
Dana-Farber Cancer Institute
Harvard Medical School

5:00 pm

Sessions End

5:00 pm

Dinner on your own

8:30-11:00 pm

Hospitality Suite

Tuesday, October 17
7:00 am

General Breakfast and Topic Specific Roundtable Discussions

7:00 am

Exhibits Open

General Session

8:00 am

NCI Director’s Report
Dr. Doug Lowy
National Cancer Institute

8:45 am

Reducing Barriers to Care
Cancer disparities result from a variety of factors including access to care, lifestyle choices such as smoking or dietary habits, and pervasive social and economic challenges. Resolving such a multi-layered problem requires a multi-level solution. Panelists will discuss a number of approaches that they have implemented to bridge the gap between the causes of cancer and effective patient care.

Moderator: Dr. Eduardo Sotomayor
GW Cancer Center

Dr. Sanjeev Arora
University of New Mexico Comprehensive Cancer Center

Ms. Mandi Pratt-Chapman
GW Cancer Center

Ms. Dana Dornsife
Lazarex Cancer Foundation

Dr. Vanessa B. Sheppard
VCU Massey Cancer Center

9:45 am

Break

10:00 am

Paying for Cancer Care: Will Washington Change the Rules?
With the change in administration and a single party majority in Congress, cancer centers are struggling to gauge the impact of Washington’s new landscape on a number of vital issues.  With the potential repeal and replacement of The Patient Protection and Affordable Care Act (ACA) as well as policy changes that may bear on the cost of oncology drugs, insurance preauthorization, Medicare and Medicaid and reimbursement rates, panelists will discuss how policymakers in Washington are reshaping healthcare.
                                                   
Moderator: Dr. Roy Jensen
The University of Kansas Cancer Center

Dr. Otis Brawley
American Cancer Society

Ms. Chiara D'Agostino
Beauty Through the Beast

Dr. Stephen Gruber
USC Norris Comprehensive Cancer Center
University of Southern California

Dr. Yousuf Zafar
Duke Cancer Institute
Duke University Medical Center

11:15 am

Update on the NCI Cancer Centers Program
This session provides an opportunity for an open dialogue about the NCI's programmatic priorities, policies, strategies and goals for the national cancer research enterprise. A discussion about the merits and challenges of these new priorities will contribute to the optimal use of limited federal cancer research funds at AACI member cancer centers.

Dr. Henry P. Ciolino
National Cancer Institute

12:00 pm

Adjourn

Program Subject to Change


Continuing Medical Education

Joint Providership Statement
Jointly provided by the American Association for Cancer Research and the Association of American Cancer Institutes.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association for Cancer Research and the Association of American Cancer Institutes. The American Association for Cancer Research is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The American Association for Cancer Research designates this live activity for a maximum of 14.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live continuing medical education activity must complete the CME Request for Credit Survey by Tuesday, December 5, 2017. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Learning Objectives
Physicians and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to administrators at their centers. As part of the program's learning objectives, all attendees should be able to describe and discuss:

•NCI's priorities, policies, strategies and goals for the national cancer research enterprise, and their relationship to academic cancer centers.
•Models of care across cancer center networks which satisfy efforts to integrate treatment services into the community.
•Implementation of immunotherapeutic strategies in the patient care model.
•Collaborations with community partners in an effort to improve access to care for patients from underserved areas.
•The complexities of implementing precision medicine at cancer centers.
•Approaches to care which bridge the gap between the causes of cancer and effective patient care.
•Changes to healthcare coverage under the new federal administration.

Americans with Disabilities Act
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please contact Jaime Anderson at 412-647-3845 or attach a note to your registration form.

Faculty Disclosure
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Target Audience
This trans-disciplinary conference is designed for basic and clinical scientists, as well as for physician-scientists from academia, industry, government, and other institutions with interest in innovative systems and technologies for diagnosing, preventing, and treating cancer and its long-term effects.

Leaders of AACI’s academic and freestanding cancer research centers, including cancer center directors, executive administrators, and other top scientific and clinical leaders—leaders from industry and government agencies as well as those of cancer research and advocacy organizations attend the meeting. All attendees have a significant impact on cancer research and patient care. Medical professionals, including oncologists, pharmacists, radiologists, nuclear medicine physicians, nurses, social workers, psychologists, cancer communication specialists, public health leaders, and other faculty members who focus on cancer.